Capillary pCO2 helps distinguishing idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction by Karen M Olsson et al.
Olsson et al. Respiratory Research  (2015) 16:34 
DOI 10.1186/s12931-015-0194-6RESEARCH Open AccessCapillary pCO2 helps distinguishing idiopathic
pulmonary arterial hypertension from pulmonary
hypertension due to heart failure with preserved
ejection fraction
Karen M Olsson*, Lisa Sommer, Jan Fuge, Tobias Welte and Marius M HoeperAbstract
Rationale: The demographics of patients with idiopathic pulmonary arterial hypertension (IPAH) are changing and
this diagnosis is increasingly being made in older patients. However, diagnostic misclassifications are common as it
may be difficult to differentiate between IPAH and pulmonary hypertension due to heart failure with preserved
ejection fraction (PH-HFpEF). We investigated the hypothesis that the capillary pCO2 (pcCO2) may help distinguishing
between idiopathic pulmonary arterial hypertension (IPAH) and pulmonary hypertension due to heart failure with
preserved ejection fraction (PH-HFpEF).
Methods: In a cross-sectional study, we retrospectively assessed pcCO2 levels (obtained from arterialized capillary blood
at the time of diagnosis) from patients with IPAH or PH-HFpEF, respectively. Receiver operated characteristics (ROC)
were used to determine the pcCO2 level providing the best discrimination between these two conditions. PcCO2
values were considered helpful if they were associated with a negative predictive value >0.9 to excluded either IPAH or
PH-HFpEF.
Results: The study enrolled 185 patients, 99 with IPAH (74% female; age 47 ± 17 years; body mass index 26 ± 5 kg/m2,
PAPm 53 ± 12 mmHg, PAWP 8 ± 3 mmHg), and 86 with PH-HFpEF (64% female; age 69 ± 10 years; body mass index
30 ± 6 kg/m2, PAPm 47 ± 10 mmHg, PAWP 21 ± 5 mmHg). PcCO2 at time of diagnosis was 33 ± 4 mmHg in the IPAH
group and 40 ± 5 mmHg in the PH-HFpEF group (p < 0.001), respectively. According to ROC analysis, a pcCO2 of
36 mmHg was the best discriminator between both entities with an area under curve of 0.87 (p < 0.001). The likelihood
of PH-HFpEF was <10% in patients with a PcCO2 < 34 mmHg, whereas the likelihood of IPAH was <10% in patients with
a PcCO2 > 41 mmHg.
Conclusions: PcCO2 levels were significantly lower in IPAH compared to PH-HFpEF and may provide useful information
in differentiating between both conditions.
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Table 1 Patient characteristics at the time of diagnosis
IPAH (n = 99) PH-HFpEF (n = 86) p-value
Age (years) 47 ± 17 69 ± 10 <0.001
Female (%) 74 64 0.101
Body mass
index (kg/m2)
26 ± 5 30 ± 6 <0.001
Diabetes (%) 19 57 <0.001
NYHA II/III/IV (n) 38/60/1 8/77/1 n/a
6 min walking
distance (m)
386 ± 136 276 ± 117 <0.001
Right atrial
pressure (mmHg)
7 ± 5 13 ± 5 <0.001
PAPm (mmHg) 53 ± 12 47 ± 10 <0.001
PAWP (mmHg) 8 ± 3 21 ± 5 <0.001
Transpulmonary
gradient (mmHg)
46 ± 13 25 ± 10 <0.001
Diastolic
gradient (mmHg)
24 ± 11 10 ± 8 <0.001
CO (L/min) 3.9 ± 1.2 4.9 ± 1.3 <0.001
CI (L/min/m2) 2.1 ± 0.6 2.5 ± 0.7 <0.001
PVR (dyn · s · cm−5) 1,017 ± 416 471 ± 218 <0.001
SvO2 (%) 64 ± 9 63 ± 8 0.368
PcaO2 (kPa) 9.5 ± 1.5 8.7 ± 1.2 0.039
PcaO2 (mmHg) 71 ± 11 65 ± 9
PcaCO2 (kPa) 4.4 ± 0.5 5.3 ± 0.7 <0.001
PcaCO2 (mmHg) 33 ± 4 40 ± 5
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According to the current classification, pulmonary hy-
pertension (PH) is divided into 5 distinct groups: (i) pul-
monary arterial hypertension (PAH), (ii) PH due to left
heart disease, (iii) PH due to lung disease and/or hy-
poxia, (iv) chronic thromboembolic pulmonary hyper-
tension (CTEPH), and (v) PH with unclear multifactorial
mechanisms [1]. For most patients with PH, the diag-
nostic classification is straightforward but in occasional
patients, the distinction between some of these condi-
tions may be difficult.
An increasing diagnostic challenge in the work-up of
patients with PH is the discrimination between idio-
pathic PAH (IPAH) and PH due to heart failure with
preserved ejection fraction (PH-HFpEF). The current
criteria for the distinction between IPAH and PH-
HFpEF have limitations [2,3]. By definition, patients with
IPAH have pre-capillary PH, i.e. a pulmonary artery wedge
pressure (PAWP) or a left ventricular end-diastolic pres-
sure (LVEDP) ≤15 mmHg, whereas patients with PH-
HFpEF are characterized by post-capillary PH as defined
by a PAWP/LVEDP >15 mmHg [2]. However, the invasive
measurements of the left ventricular filling pressures can
be misleading, both for technical as well as for physio-
logical reasons [4]. Hence, PAWP/LVEDP measurements
may yield values >15 mmHg in patients with PAH and -
arguably more common - values ≤15 mmHg in patients
with HFpEF, especially if left heart disease is optimally
treated [5-7].
Thus, a single PAWP/LVEDP cut-off value is not
always sufficient to allow an accurate diagnosis of pre-
or post-capillary PH in each individual patient. This dis-
tinction, however, is of fundamental practical importance
as the treatment of IPAH differs substantially from the
treatment of patients with PH-HFpEF [8].
In the past, this problem was less evident as IPAH was
originally considered predominantly a disease of younger
women, and these patients are usually not at risk for de-
veloping HFpEF. More recently, however, IPAH is in-
creasingly diagnosed in older patients, many of whom
presenting with risk factors for developing left heart disease
[9-11]. In a recently published report United Kingdom
Pulmonary Hypertension registry, 13.5% of the patients
were diagnosed with IPAH at an age >70 years, and in the
European-based COMPERA registry, this proportion was
even 50% [9,11]. It is possible that some of these patients
were misclassified. Several conditions may mimic PAH and
among those, HFpEF is the most common [2]. However all
of the older patients in the abovementioned registries had
a pulmonary arterial wedge pressure (PAWP) ≤15 mmHg,
which – in a strict sense – would exclude a diagnosis of
PH-HFpEF [9,11].
Hence measuring PAWP/LVEDP alone is not always
sufficient to delineate IPAH from PH-HFpEF, and acomprehensive diagnostic assessment is required in
order to ensure an accurate distinction between these
two conditions. Risk factors for HFpEF include an older
age, obesity, hypertension, diabetes and coronary heart
disease [2,3]. The presence of echocardiographic signs of
left ventricular diastolic dysfunction including an en-
larged left atrium as well as the presence of permanent
atrial fibrillation increase the likelihood of HFpEF, but
none of these features excludes a diagnosis of IPAH.
It would be useful to have additional non-invasive vari-
ables that help distinguishing IPAH from PH-HFpEF. One
potential candidate could be capillary pCO2 (pcCO2).
PcCO2 can be obtained from arterialized earlobe sampling
and accurately reflects arterial pCO2 [12-15]. Hyperventi-
lation at rest and during exercise is a known feature of
heart failure and PAH [16-19]. The mechanisms causing
hyperventilation in these patients are incompletely under-
stood, but increased physiologic dead space and, probably
more importantly, increased chemosensitivity seem to play
an important role [17,20]. Capillary pcCO2 tends to be
more profoundly reduced in patients with IPAH [16,21]
than in patients with PH-HFpEF [20,22]. Hence, we hy-
pothesized that pcCO2 measurements may be helpful to
discriminate between both conditions.
Figure 1 Histogram showing the distribution of capillary pCO2 in patients with idiopathic pulmonary arterial hypertension (red) and
patients with pulmonary hypertension due to heart failure with preserved ejection fraction (green) in 5 mmHg intervals.
Figure 2 Receiver operated characteristics (ROC) curve showing
the diagnostic performance of pcCO2 in distinguishing idiopathic
pulmonary arterial hypertension (IPAH) from pulmonary
hypertension in patients with heart failure and preserved
ejection fraction (PH-HFpEF).
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Since April 2012, the Pulmonary Hypertension Clinic at
Hannover Medical School has implemented an elec-
tronic database capturing all patients treated for PH. We
used this database for a cross-sectional analysis of pa-
tients with well characterized IPAH or PH-HFpEF, re-
spectively, based on the diagnostic criteria listed below.
All variables analyzed and presented in this manuscript
were obtained at the time of diagnosis, i.e. the time of
the first diagnostic right heart catheterization.
General inclusion criteria for both groups were a body
mass index <40 kg/m2, normal or near normal pulmonary
function test results including a total lung capacity >80%
predicted, a forced expiratory capacity in 1 s >60% pre-
dicted, a diffusion capacity for carbon monoxide >40%
predicted, the absence or more than mild parenchymal
abnormalities on chest computed tomography, and the
need for non-invasive ventilation support for sleep-related
breathing disorders. CTEPH was ruled out by ventilation-
perfusion scintigraphy, and pulmonary angiography if
needed, in all patients. All patients underwent right heart
catheterization because of suspected severe PH or PAH,
respectively, at the time of diagnosis with determination
of right atrial pressure, mean pulmonary artery pressure
(PAPm), PAWP and mixed venous oxygen saturation
(SvO2). The pressure transducer was set at mid-thoraciclevel for all procedures. Cardiac output was measured
by thermodilution; pulmonary vascular resistance (PVR),
cardiac index (CI), transpulmonary gradient (TPG) and
diastolic pulmonary gradient (DPG) were calculated by
standard formula.
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following criteria: PAPm ≥25 mmHg, PAWP ≤15 mmHg,
PVR >240 dyn · s · cm−5, sinus rhythm at time of diagno-
sis, left ventricular ejection fraction >60% and normal
size of the left atrium on echocardiography. A diagnosis
of PH-HFpEF was based on the following criteria:
PAPm ≥25 mmHg, PAWP >15 mmHg, left ventricular
ejection fraction >50%, normal end-systolic and end-
diastolic left ventricular diameters, and signs of diastolic
dysfunction including the presence of an enlarged left
atrium on echocardiography.
All patients provided written informed consent and
the study was approved by the local ethics committee.Figure 3 Diagnostic performance of pCO2. a) Sensitivity and specificity o
value of pcCO2 for a diagnosis of PH-HFpEF.Right heart catheterization
Right heart catheterizations were performed via a jugular
approach following a standardized protocol. The pres-
sure transducer was zeroed at the mid-thoracic level and
all pressure readings were done at end-expiration [23].
Cardiac output was measured by thermodilution tech-
nique with the reported value being the average of at
least three recordings with less than 10% variation.
Blood gas analyses
Experienced technicians obtained arterialized capillary
blood gases from earlobes after a resting period ≥10 min
while patients were breathing room air. The bloodf pcCO2 for a diagnosis of PH-HFpEF. b) Positive and negative predictive
Table 2 Correlations between pcCO2 and hemodynamic
variables
IPAH PH-HFpEF
r p r p
Age at diagnosis 0.062 0.544 0.432* <0.001
BMI 0.231 0.021 0.057 0.630
6MWD 0.141 0.641 −0.022 0.846
RA 0.063 0.586 −0.012 0.923
PAPm −0.144 0.155 −0.027 0.810
PAWP 0.051 0.638 0.033 0.766
CO 0.182 0.147 0.296 0.028
CI 0.052 0.658 0.232 0.080
PVR −0.278 0.009 −0.203 0.105
SvO2 0.118 0.320 0.179 0.210
PaO2 0.087 0.612 0.123 0.534
*Bold numbers reflect statistically significant associations.
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device (Radiometer, Copenhagen).
Statistical analysis
Data are shown as mean ± SD, unless indicated other-
wise. For comparison of the two patient populations,
Fisher’s exact test, Chi-square test and two-sided paired
T-test were used as appropriate. Potential associations
between pcCO2 and clinical variables were assessed with
Pearson’s correlation analysis and two-sided testing for
significance. In order to identify the pcCO2 level with
the highest power to discriminate between IPAH and
PH-HFpEF, receiver operated characteristics (ROC) curves
were drawn and the area under the curve (AUC) was cal-
culated. The cut-off value that resulted in the highest
product of sensitivity and specificity was considered the
best diagnostic pcCO2 value. Sensitivity, specificity, posi-
tive predictive values and negative predictive values were
calculated assuming an equal pre-test probability of both
conditions. PcCO2 values were arbitrarily considered use-
ful for diagnostic purposes if they were associated with a
negative predictive value >0.9 to excluded either IPAH or
PH-HFpEF.
Results
The study enrolled 185 patients; 99 with IPAH and 86
with PH-HFpEF. The patient characteristics are shown in
Table 1. Compared to patients with PH-HFpEF, patients
with IPAH were younger, had a lower body mass index
and a lower likelihood of diabetes, while exercise capacity
was less compromised. On right heart catheterization, pa-
tients with IPAH had higher values of PAPm and PVR
whereas cardiac output, cardiac index, and right atrial
pressures were lower. The arterial oxygen tension (paO2)
was mildly reduced in both groups.
PcCO2 at time of diagnosis was 33 ± 4 mmHg in the
IPAH group and 40 ± 5 mmHg in the PH-HFpEF group
(p < 0.001), respectively (Figure 1). According to ROC
analysis, a pcCO2 of 36 mmHg was the best discrimi-
nator between both entities with an area under curve of
0.868 (95% confidence interval, 0.816 – 0.920; p < 0.001;
Figure 2). The lower pcCO2, the higher was the like-
lihood of IPAH and vice versa (Figure 3). PcCO2 values
between 34 and 41 mmHg had limited discriminatory
power, but PcCO2 values outside these margins provide
valuable information. Assuming equal pre-test probabi-
lity for each diagnosis, any PcCO2 < 34 mmHg excluded the
presence of PH-HFpEF with a likelihood of >90%, whereas
the likelihood of IPAH was <10% in patients with any
PcCO2 > 41 mmHg (Figure 3). PcCO2 values >41 mmHg
were found in 14% and PcCO2 levels <34 mmHg in 35% of
the patients in this study, respectively; thus PcCO2 mea-
surements provided relevant diagnostic information in 49%
of the patients in this series.Correlations between pcCO2 and clinical variables
In patients in with IPAH, pcCO2 correlated with BMI
and inversely with PVR. In the PH-HFpEF group, pcCO2
correlated with age at diagnosis and cardiac output. Even
if statistically significant, all these correlations were weak
(Table 2).
Discussion
The present data confirm clinical observations that
pcCO2 values tend to be lower in patients with IPAH
compared to patients with PH-HFpEF. The average
pcCO2 in patients with PH-HFpEF was 40 mmHg, i.e. in
the normal range. In contrast, the average pcCO2 in pa-
tients with IPAH was 33 mmHg, i.e. markedly reduced
compared to normal values. A pcCO2 of 36 mmHg was
the best cut-off for discriminating between IPAH and
PH-HFpEF. According to ROC analysis, the AUC was
0.868 for this value, suggesting that pcCO2 may be help-
ful in distinguishing between both conditions. The lower
the pcCO2, the lower the likelihood of PH-HFpEF and
vice versa.
The physiological explanation for the low pcCO2 in
IPAH is not entirely clear. A previous study on patients
with IPAH also found a low pcCO2 at the time of diag-
nosis [16]. The median pcCO2 in that study was 32 mmHg,
i.e. very similar to the average value of 33 mmHg in the
present IPAH population. In the previous study, there was
a significant, albeit weak, correlation between pcCO2 and
cardiac output [16], which was not found in the present
IPAH population.
The patients with PH-HFpEF enrolled in the present
series had rather severe PH with a PAPm of 47 ± 10 mmHg.
The average transpulmonary gradient was 25 ± 10 mmHg,
the diastolic gradient 10 ± 8 mmHg, and the PVR
471 ± 218 dyn · s · cm−5, indicating that the majority of
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form of PH [2,24]. This is a population of patients that
may be easily misclassified as IPAH, and it may be particu-
larly such patients in whom pcCO2 measurements may
provide valuable information.
Our study has several strength and limitations.
Strengths include the relatively large sample size of well-
characterized patients, all of whom had undergone a
rigorous diagnostic assessment including right heart
catheterization at the time of diagnosis. Limitations in-
clude the single center design, the lack of a validation
cohort and the fact that our study did not further eluci-
date the mechanisms causing hypocarbia in patients with
IPAH. In addition, our HFpEF population was unique in
that most of these patients suffered from severe PH, pre-
sumably owing to a referral bias as these patients were
referred to our center for evaluation of PH, and not of
HFpEF.
The fact that we recorded all pressure readings at end-
expiration is in line with current recommendations
[23,25]. Several experts have pointed out that this ap-
proach may result in an overestimation of these pres-
sures, most importantly the PAWP [26,27]. However, we
excluded patients with lung disease so that these differ-
ences should have been marginal in our patients. The
fact that the mean PAWP in our HFpEF population was
21 mmHg compared to 8 mmHg in our IPAH popula-
tion, is reassuring. Finally, our results may not be applic-
able to patients with additional confounders, which may
affect pcCO2, such as morbid obesity or underlying lung
disease.
Conclusion
Our data show that pcCO2 is significantly lower in pa-
tients with IPAH compared to patients with PH-HFpEF
and may help distinguishing between both conditions.
Further studies are needed to determine the value of
pcCO2 in the diagnostic work-up of patients with PH.
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